CN105891511A - 用于循环肿瘤细胞和中性粒细胞鉴定的探针及试剂盒 - Google Patents
用于循环肿瘤细胞和中性粒细胞鉴定的探针及试剂盒 Download PDFInfo
- Publication number
- CN105891511A CN105891511A CN201610292929.5A CN201610292929A CN105891511A CN 105891511 A CN105891511 A CN 105891511A CN 201610292929 A CN201610292929 A CN 201610292929A CN 105891511 A CN105891511 A CN 105891511A
- Authority
- CN
- China
- Prior art keywords
- circulating tumor
- tumor cell
- probe
- neutrophilic granulocyte
- anca
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 208000005443 Circulating Neoplastic Cells Diseases 0.000 title claims abstract description 41
- 239000000523 sample Substances 0.000 title claims abstract description 37
- 210000004493 neutrocyte Anatomy 0.000 title abstract 5
- 101000738771 Homo sapiens Receptor-type tyrosine-protein phosphatase C Proteins 0.000 claims abstract description 27
- 102100037422 Receptor-type tyrosine-protein phosphatase C Human genes 0.000 claims abstract description 27
- XGWFJBFNAQHLEF-UHFFFAOYSA-N 9-anthroic acid Chemical compound C1=CC=C2C(C(=O)O)=C(C=CC=C3)C3=CC2=C1 XGWFJBFNAQHLEF-UHFFFAOYSA-N 0.000 claims abstract description 25
- 102000011782 Keratins Human genes 0.000 claims abstract description 22
- 108010076876 Keratins Proteins 0.000 claims abstract description 22
- 239000007850 fluorescent dye Substances 0.000 claims abstract description 21
- 239000003086 colorant Substances 0.000 claims abstract description 3
- 210000003714 granulocyte Anatomy 0.000 claims description 39
- 230000003448 neutrophilic effect Effects 0.000 claims description 37
- 210000004027 cell Anatomy 0.000 claims description 29
- 238000012360 testing method Methods 0.000 claims description 18
- 238000005406 washing Methods 0.000 claims description 16
- FWBHETKCLVMNFS-UHFFFAOYSA-N 4',6-Diamino-2-phenylindol Chemical compound C1=CC(C(=N)N)=CC=C1C1=CC2=CC=C(C(N)=N)C=C2N1 FWBHETKCLVMNFS-UHFFFAOYSA-N 0.000 claims description 14
- 238000000926 separation method Methods 0.000 claims description 8
- 239000007788 liquid Substances 0.000 claims description 7
- 239000001963 growth medium Substances 0.000 claims description 5
- 241001494479 Pecora Species 0.000 claims description 4
- 239000006146 Roswell Park Memorial Institute medium Substances 0.000 claims description 4
- 229920004890 Triton X-100 Polymers 0.000 claims description 4
- 239000013504 Triton X-100 Substances 0.000 claims description 4
- 239000000834 fixative Substances 0.000 claims description 4
- 230000007935 neutral effect Effects 0.000 claims description 4
- 210000002966 serum Anatomy 0.000 claims description 4
- 101000998011 Homo sapiens Keratin, type I cytoskeletal 19 Proteins 0.000 claims description 3
- 101000994460 Homo sapiens Keratin, type I cytoskeletal 20 Proteins 0.000 claims description 3
- 102100033420 Keratin, type I cytoskeletal 19 Human genes 0.000 claims description 3
- 102100032700 Keratin, type I cytoskeletal 20 Human genes 0.000 claims description 3
- 230000001413 cellular effect Effects 0.000 claims description 3
- PYWVYCXTNDRMGF-UHFFFAOYSA-N rhodamine B Chemical compound [Cl-].C=12C=CC(=[N+](CC)CC)C=C2OC2=CC(N(CC)CC)=CC=C2C=1C1=CC=CC=C1C(O)=O PYWVYCXTNDRMGF-UHFFFAOYSA-N 0.000 claims description 3
- 238000001215 fluorescent labelling Methods 0.000 claims description 2
- ZMZDMBWJUHKJPS-UHFFFAOYSA-N hydrogen thiocyanate Natural products SC#N ZMZDMBWJUHKJPS-UHFFFAOYSA-N 0.000 claims description 2
- GRHBQAYDJPGGLF-UHFFFAOYSA-N isothiocyanic acid Chemical compound N=C=S GRHBQAYDJPGGLF-UHFFFAOYSA-N 0.000 claims description 2
- GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 claims 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 abstract description 13
- 201000005202 lung cancer Diseases 0.000 abstract description 9
- 208000020816 lung neoplasm Diseases 0.000 abstract description 9
- 210000005259 peripheral blood Anatomy 0.000 abstract description 8
- 239000011886 peripheral blood Substances 0.000 abstract description 8
- 206010027476 Metastases Diseases 0.000 abstract description 6
- 230000009401 metastasis Effects 0.000 abstract description 6
- 210000005266 circulating tumour cell Anatomy 0.000 description 39
- 238000000034 method Methods 0.000 description 19
- 210000004369 blood Anatomy 0.000 description 13
- 239000008280 blood Substances 0.000 description 13
- 239000002953 phosphate buffered saline Substances 0.000 description 13
- 239000000243 solution Substances 0.000 description 9
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 8
- 206010028980 Neoplasm Diseases 0.000 description 7
- 238000001514 detection method Methods 0.000 description 7
- 238000004043 dyeing Methods 0.000 description 7
- 238000012546 transfer Methods 0.000 description 7
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
- 238000005516 engineering process Methods 0.000 description 6
- 238000010166 immunofluorescence Methods 0.000 description 6
- 210000004881 tumor cell Anatomy 0.000 description 6
- 239000006285 cell suspension Substances 0.000 description 5
- 102000018651 Epithelial Cell Adhesion Molecule Human genes 0.000 description 4
- 108010066687 Epithelial Cell Adhesion Molecule Proteins 0.000 description 4
- 238000002372 labelling Methods 0.000 description 4
- 239000002253 acid Substances 0.000 description 3
- 239000011324 bead Substances 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 3
- 210000003677 hemocyte Anatomy 0.000 description 3
- 210000000265 leukocyte Anatomy 0.000 description 3
- 206010025482 malaise Diseases 0.000 description 3
- 239000012528 membrane Substances 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 230000000877 morphologic effect Effects 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 206010061309 Neoplasm progression Diseases 0.000 description 2
- 206010057249 Phagocytosis Diseases 0.000 description 2
- 230000017531 blood circulation Effects 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 230000004087 circulation Effects 0.000 description 2
- 230000000052 comparative effect Effects 0.000 description 2
- 239000000975 dye Substances 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 229940088598 enzyme Drugs 0.000 description 2
- 210000002919 epithelial cell Anatomy 0.000 description 2
- 230000014509 gene expression Effects 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 238000002955 isolation Methods 0.000 description 2
- 238000009630 liquid culture Methods 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 238000005374 membrane filtration Methods 0.000 description 2
- 108020004707 nucleic acids Proteins 0.000 description 2
- 150000007523 nucleic acids Chemical class 0.000 description 2
- 102000039446 nucleic acids Human genes 0.000 description 2
- 230000008782 phagocytosis Effects 0.000 description 2
- 238000003752 polymerase chain reaction Methods 0.000 description 2
- 238000004321 preservation Methods 0.000 description 2
- 238000012797 qualification Methods 0.000 description 2
- 230000035945 sensitivity Effects 0.000 description 2
- 230000019491 signal transduction Effects 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 210000003462 vein Anatomy 0.000 description 2
- BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 description 1
- 102000004157 Hydrolases Human genes 0.000 description 1
- 108090000604 Hydrolases Proteins 0.000 description 1
- 108090000723 Insulin-Like Growth Factor I Proteins 0.000 description 1
- JLVVSXFLKOJNIY-UHFFFAOYSA-N Magnesium ion Chemical compound [Mg+2] JLVVSXFLKOJNIY-UHFFFAOYSA-N 0.000 description 1
- 206010027336 Menstruation delayed Diseases 0.000 description 1
- 102000016943 Muramidase Human genes 0.000 description 1
- 108010014251 Muramidase Proteins 0.000 description 1
- 108010062010 N-Acetylmuramoyl-L-alanine Amidase Proteins 0.000 description 1
- 102000004160 Phosphoric Monoester Hydrolases Human genes 0.000 description 1
- 108090000608 Phosphoric Monoester Hydrolases Proteins 0.000 description 1
- 108010004729 Phycoerythrin Proteins 0.000 description 1
- 235000018259 Solanum vestissimum Nutrition 0.000 description 1
- 240000002825 Solanum vestissimum Species 0.000 description 1
- 102000013275 Somatomedins Human genes 0.000 description 1
- 244000297179 Syringa vulgaris Species 0.000 description 1
- 235000004338 Syringa vulgaris Nutrition 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 210000002469 basement membrane Anatomy 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 229910001424 calcium ion Inorganic materials 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 230000035605 chemotaxis Effects 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 238000000432 density-gradient centrifugation Methods 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000000684 flow cytometry Methods 0.000 description 1
- 238000000799 fluorescence microscopy Methods 0.000 description 1
- 238000012757 fluorescence staining Methods 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 229940000351 hemocyte Drugs 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 238000003365 immunocytochemistry Methods 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 231100000518 lethal Toxicity 0.000 description 1
- 230000001665 lethal effect Effects 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 210000003712 lysosome Anatomy 0.000 description 1
- 230000001868 lysosomic effect Effects 0.000 description 1
- 229960000274 lysozyme Drugs 0.000 description 1
- 235000010335 lysozyme Nutrition 0.000 description 1
- 239000004325 lysozyme Substances 0.000 description 1
- 229910001425 magnesium ion Inorganic materials 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 230000001394 metastastic effect Effects 0.000 description 1
- 206010061289 metastatic neoplasm Diseases 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 210000005087 mononuclear cell Anatomy 0.000 description 1
- 210000000440 neutrophil Anatomy 0.000 description 1
- 238000005192 partition Methods 0.000 description 1
- 230000000505 pernicious effect Effects 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- JGVWCANSWKRBCS-UHFFFAOYSA-N tetramethylrhodamine thiocyanate Chemical compound [Cl-].C=12C=CC(N(C)C)=CC2=[O+]C2=CC(N(C)C)=CC=C2C=1C1=CC=C(SC#N)C=C1C(O)=O JGVWCANSWKRBCS-UHFFFAOYSA-N 0.000 description 1
- 238000010257 thawing Methods 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000005748 tumor development Effects 0.000 description 1
- 230000001173 tumoral effect Effects 0.000 description 1
- 210000001835 viscera Anatomy 0.000 description 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6884—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids from lung
-
- C—CHEMISTRY; METALLURGY
- C09—DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; COMPOSITIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
- C09K—MATERIALS FOR MISCELLANEOUS APPLICATIONS, NOT PROVIDED FOR ELSEWHERE
- C09K11/00—Luminescent, e.g. electroluminescent, chemiluminescent materials
- C09K11/06—Luminescent, e.g. electroluminescent, chemiluminescent materials containing organic luminescent materials
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N1/00—Sampling; Preparing specimens for investigation
- G01N1/28—Preparing specimens for investigation including physical details of (bio-)chemical methods covered elsewhere, e.g. G01N33/50, C12Q
- G01N1/30—Staining; Impregnating ; Fixation; Dehydration; Multistep processes for preparing samples of tissue, cell or nucleic acid material and the like for analysis
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N1/00—Sampling; Preparing specimens for investigation
- G01N1/28—Preparing specimens for investigation including physical details of (bio-)chemical methods covered elsewhere, e.g. G01N33/50, C12Q
- G01N1/38—Diluting, dispersing or mixing samples
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N21/00—Investigating or analysing materials by the use of optical means, i.e. using sub-millimetre waves, infrared, visible or ultraviolet light
- G01N21/62—Systems in which the material investigated is excited whereby it emits light or causes a change in wavelength of the incident light
- G01N21/63—Systems in which the material investigated is excited whereby it emits light or causes a change in wavelength of the incident light optically excited
- G01N21/64—Fluorescence; Phosphorescence
- G01N21/6486—Measuring fluorescence of biological material, e.g. DNA, RNA, cells
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/531—Production of immunochemical test materials
- G01N33/532—Production of labelled immunochemicals
- G01N33/533—Production of labelled immunochemicals with fluorescent label
-
- C—CHEMISTRY; METALLURGY
- C09—DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; COMPOSITIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
- C09K—MATERIALS FOR MISCELLANEOUS APPLICATIONS, NOT PROVIDED FOR ELSEWHERE
- C09K2211/00—Chemical nature of organic luminescent or tenebrescent compounds
- C09K2211/10—Non-macromolecular compounds
- C09K2211/1018—Heterocyclic compounds
- C09K2211/1025—Heterocyclic compounds characterised by ligands
- C09K2211/1029—Heterocyclic compounds characterised by ligands containing one nitrogen atom as the heteroatom
-
- C—CHEMISTRY; METALLURGY
- C09—DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; COMPOSITIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
- C09K—MATERIALS FOR MISCELLANEOUS APPLICATIONS, NOT PROVIDED FOR ELSEWHERE
- C09K2211/00—Chemical nature of organic luminescent or tenebrescent compounds
- C09K2211/10—Non-macromolecular compounds
- C09K2211/1018—Heterocyclic compounds
- C09K2211/1025—Heterocyclic compounds characterised by ligands
- C09K2211/1088—Heterocyclic compounds characterised by ligands containing oxygen as the only heteroatom
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N1/00—Sampling; Preparing specimens for investigation
- G01N1/28—Preparing specimens for investigation including physical details of (bio-)chemical methods covered elsewhere, e.g. G01N33/50, C12Q
- G01N1/30—Staining; Impregnating ; Fixation; Dehydration; Multistep processes for preparing samples of tissue, cell or nucleic acid material and the like for analysis
- G01N2001/302—Stain compositions
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/12—Pulmonary diseases
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- General Health & Medical Sciences (AREA)
- Pathology (AREA)
- General Physics & Mathematics (AREA)
- Biochemistry (AREA)
- Analytical Chemistry (AREA)
- Physics & Mathematics (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Food Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- Biotechnology (AREA)
- Cell Biology (AREA)
- Microbiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Materials Engineering (AREA)
- Organic Chemistry (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Abstract
Description
Claims (10)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201610292929.5A CN105891511A (zh) | 2016-05-04 | 2016-05-04 | 用于循环肿瘤细胞和中性粒细胞鉴定的探针及试剂盒 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201610292929.5A CN105891511A (zh) | 2016-05-04 | 2016-05-04 | 用于循环肿瘤细胞和中性粒细胞鉴定的探针及试剂盒 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN105891511A true CN105891511A (zh) | 2016-08-24 |
Family
ID=56702223
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201610292929.5A Pending CN105891511A (zh) | 2016-05-04 | 2016-05-04 | 用于循环肿瘤细胞和中性粒细胞鉴定的探针及试剂盒 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN105891511A (zh) |
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN107462724A (zh) * | 2016-08-30 | 2017-12-12 | 上海浦美生物医药科技有限公司 | 血液中循环肿瘤细胞的检测方法 |
CN109856388A (zh) * | 2018-11-29 | 2019-06-07 | 北京优迅医学检验实验室有限公司 | 循环肿瘤细胞的捕获方法及捕获试剂盒 |
CN111060688A (zh) * | 2019-12-27 | 2020-04-24 | 深圳天烁生物科技有限公司 | 胃肠道恶性肿瘤循环肿瘤细胞检测试剂盒及检测方法 |
CN111380729A (zh) * | 2018-12-27 | 2020-07-07 | 上海细胞治疗集团有限公司 | 一种细胞涂片的制备方法及其应用 |
CN111596053A (zh) * | 2019-02-21 | 2020-08-28 | 南方医科大学南方医院 | Tpn分子在制备循环肿瘤细胞检测试剂中的用途及检测试剂和试剂盒 |
CN111812324A (zh) * | 2020-06-22 | 2020-10-23 | 东南大学 | 一种检测肺癌循环肿瘤细胞的方法 |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2009143149A2 (en) * | 2008-05-19 | 2009-11-26 | Veridex, Llc | Improved imaging of immunomagnetically enriched rare cells |
CN102690786A (zh) * | 2012-06-05 | 2012-09-26 | 武汉格蓝丽富科技有限公司 | 一种细胞富集、分离、提取的方法和仪器及单细胞分析方法 |
CN105115878A (zh) * | 2015-09-11 | 2015-12-02 | 上海交通大学 | 一种循环肿瘤细胞检测试剂盒及其制备方法和应用 |
-
2016
- 2016-05-04 CN CN201610292929.5A patent/CN105891511A/zh active Pending
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2009143149A2 (en) * | 2008-05-19 | 2009-11-26 | Veridex, Llc | Improved imaging of immunomagnetically enriched rare cells |
CN102690786A (zh) * | 2012-06-05 | 2012-09-26 | 武汉格蓝丽富科技有限公司 | 一种细胞富集、分离、提取的方法和仪器及单细胞分析方法 |
CN105115878A (zh) * | 2015-09-11 | 2015-12-02 | 上海交通大学 | 一种循环肿瘤细胞检测试剂盒及其制备方法和应用 |
Non-Patent Citations (3)
Title |
---|
HUI-YING LIU等: "Improved method increases sensitivity for circulating hepatocellular carcinoma cells", 《WORLD JOURNAL OF GASTROENTEROLOGY》 * |
李天星: "《现代临床医学免疫学检验技术》", 30 September 2014 * |
王建中: "流式细胞术分析血液淋巴细胞免疫表型方法学研究", 《中华检验医学杂志》 * |
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN107462724A (zh) * | 2016-08-30 | 2017-12-12 | 上海浦美生物医药科技有限公司 | 血液中循环肿瘤细胞的检测方法 |
CN109856388A (zh) * | 2018-11-29 | 2019-06-07 | 北京优迅医学检验实验室有限公司 | 循环肿瘤细胞的捕获方法及捕获试剂盒 |
CN111380729A (zh) * | 2018-12-27 | 2020-07-07 | 上海细胞治疗集团有限公司 | 一种细胞涂片的制备方法及其应用 |
CN111596053A (zh) * | 2019-02-21 | 2020-08-28 | 南方医科大学南方医院 | Tpn分子在制备循环肿瘤细胞检测试剂中的用途及检测试剂和试剂盒 |
CN111060688A (zh) * | 2019-12-27 | 2020-04-24 | 深圳天烁生物科技有限公司 | 胃肠道恶性肿瘤循环肿瘤细胞检测试剂盒及检测方法 |
CN111812324A (zh) * | 2020-06-22 | 2020-10-23 | 东南大学 | 一种检测肺癌循环肿瘤细胞的方法 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN105891511A (zh) | 用于循环肿瘤细胞和中性粒细胞鉴定的探针及试剂盒 | |
CN104007257B (zh) | 一种检测非体液性稀有有核细胞的方法和试剂盒 | |
CN106635995B (zh) | 一种循环肿瘤细胞阴性富集方法 | |
CN101587043B (zh) | 从生物体液样本中富集与检测稀有细胞的整合方法 | |
CN105785005A (zh) | 一种循环肿瘤细胞的检测试剂盒及其应用 | |
CN106370867B (zh) | 一种联合检测评估肝癌肝移植术后转移复发风险的试剂盒 | |
CN110632292A (zh) | 一种检测pd-l1和cd8抗原的免疫荧光试剂盒及应用方法 | |
CN107402296A (zh) | 一种循环肿瘤细胞的免疫荧光染色及判读方法 | |
CN110389219B (zh) | 一种上皮间质混合型及pd-l1阳性循环肿瘤细胞的富集检测方法 | |
CN111812323B (zh) | 己糖激酶2用于体液样本中稀有肿瘤细胞检测及试剂盒 | |
CN104677810A (zh) | 嗜碱性粒细胞活化的检测试剂盒及其使用方法 | |
CN106771185A (zh) | 一种鼻咽癌循环肿瘤细胞检测试剂盒 | |
CN109187977A (zh) | 一种检测her2抗原不同位点的免疫荧光试剂盒及应用 | |
CN105087775A (zh) | 一种基于稀有细胞检测c-MET/CEP7基因状态的方法及相关试剂盒 | |
CN111812071A (zh) | 一种新型循环肿瘤细胞的鉴定技术 | |
CN104990905B (zh) | 一种基于固相酶联免疫荧光斑点的肝癌转移诊断试剂盒 | |
Bu et al. | Enhancement of isolation sensitivity for the viable heterogeneous circulating tumor cells swelled by hypo-osmotic pressure | |
CN105223360A (zh) | 鉴别检测正常浆细胞和克隆性浆细胞的试剂盒及其应用 | |
CN102313813B (zh) | 从生物体液样本中富集与检测稀有细胞的整合方法 | |
CN117192121A (zh) | 用于mds和/或aml微小残留病检测的抗体组合物及其应用 | |
CN106480188B (zh) | 转移性前列腺癌早期预测的分子探针、试剂盒及该分子探针的应用 | |
CN108982874A (zh) | 一种检测人前列腺癌抗原psa、ar-v7的免疫荧光试剂盒及应用 | |
CN110954701B (zh) | 一种肝纤维化或肝硬化的诊断试剂盒 | |
WO2021010369A1 (ja) | ウイルスを用いた循環腫瘍細胞の検出方法 | |
CN114460297A (zh) | 一种用于检测血液中循环前列腺上皮细胞的免疫荧光试剂盒及其使用方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C41 | Transfer of patent application or patent right or utility model | ||
TA01 | Transfer of patent application right |
Effective date of registration: 20160901 Address after: 510000, Guangdong, Guangzhou, Guangzhou, Haizhuqu District International Biological Island, No. four, No. 9, No. 1, c101-3 Applicant after: GUANGZHOU MYGENE MEDICAL TECHNOLOGY CO.,LTD. Applicant after: The First Affiliated Hospital,Sun Yat-sen University Address before: 510000 No. two, No. 58, Zhongshan Road, Guangdong, Guangzhou Applicant before: The First Affiliated Hospital,Sun Yat-sen University |
|
RJ01 | Rejection of invention patent application after publication |
Application publication date: 20160824 |
|
RJ01 | Rejection of invention patent application after publication |